Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer

NCT02751710 is registered in ClinicalTrials.gov with Ontario Clinical Oncology Group (OCOG) as lead sponsor.

NCT NCT02751710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02751710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Phase
Not applicable
Overall status
Completed
Start date
December 6, 2016
Completion date
March 31, 2023
Enrollment
369 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

stage iib breast cancer (t3n0), stage iii breast cancer (t0n2, t1n2, t2n2, t3n1, 2 or t4)